Trials / Completed
CompletedNCT01018979
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
A Phase II, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- GPCR Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG-0054 (2.24 mg/kg) | TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions) |
| DRUG | TG-0054 (3.14 mg/kg) | TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions) |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2009-11-25
- Last updated
- 2021-05-11
- Results posted
- 2015-01-15
Locations
6 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01018979. Inclusion in this directory is not an endorsement.